GC Biopharma Corp. (KRX:006280)

South Korea flag South Korea · Delayed Price · Currency is KRW
125,800
+1,600 (1.29%)
At close: May 2, 2025, 3:30 PM KST
10.06%
Market Cap 1.44T
Revenue (ttm) 1.68T
Net Income (ttm) -26.28B
Shares Out 11.41M
EPS (ttm) -2,302.62
PE Ratio n/a
Forward PE n/a
Dividend 1,500.00 (1.19%)
Ex-Dividend Date Dec 27, 2024
Volume 16,902
Average Volume 21,623
Open 124,700
Previous Close 124,200
Day's Range 124,700 - 127,600
52-Week Range 110,100 - 181,800
Beta 1.41
RSI 57.14
Earnings Date May 15, 2025

About GC Biopharma

GC Biopharma Corp., a biopharmaceutical company, develops and sells pharmaceutical drugs in South Korea and internationally. It provides over-the-counter drugs, such as Acustop Cataplasma for Analgesic and anti-inflammatory effect; Kenhancer plaster for anti-inflammatory; and Zenol Cool Type and Zenol Mild Hot Type drugs to treat anti-inflammatory and pain relief. The company also offers Albumin-GCC injection (inj.) for hypoalbuminemia and shock in acute hemorrhage, as well as low synthesis of albumin; Antithrombin-III (AT-III) inj. for heredit... [Read more]

Sector Healthcare
Founded 1967
Employees 2,009
Stock Exchange Korea Stock Exchange
Ticker Symbol 006280
Full Company Profile

Financial Performance

In 2024, GC Biopharma's revenue was 1.68 trillion, an increase of 3.27% compared to the previous year's 1.63 trillion. Losses were -26.28 billion, -1.32% less than in 2023.

Financial Statements

News

There is no news available yet.